Company intelligence / Profile preview
Luye Pharma Group
Yantai, Chinaluye.cn ↗
- Ownership
- Public · 2186
- Employees
- ~10000
- Development stage
- Other
01
Overview
Luye Pharma has received approval for 16 innovative products in multiple global markets since 2021. Notable recent approvals include Rykindo® and Erzofri® by the FDA, with Rykindo® being the first innovative CNS drug developed by a Chinese company approved for the U.S. market.
- Therapeutic areas
- OncologyPsychiatryNeurology
- Modalities
- Small moleculesmicrospheresliposomestransdermal systemsantibodiesnucleic acidsmRNAcell therapy (CAR-T)
- Industry
- Biotech
02
Drug pipeline
39 assets38 more assets in the full pipeline.
03
Partnerships
AstraZenecaAcino
04
Financials
- Market cap
- $853.4M
- Total revenue
- $945.8M
- Enterprise value
- $1.1B
Beyond the preview
Go deeper on Luye Pharma Group.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Luye Pharma Group.